Quarterly report pursuant to Section 13 or 15(d)

Business Combination (Details) - Schedule of anticipated integration costs related to the acquired company

v3.22.2.2
Business Combination (Details) - Schedule of anticipated integration costs related to the acquired company - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2022
PASITHEA THERAPEUTICS CORP [Member]    
Acquired Indefinite-Lived Intangible Assets [Line Items]    
Revenues $ 13,581 $ 27,239
Cost of services 15,101 28,038
Gross margin (1,520) (799)
Operating expenses:    
Selling, general and administrative 3,078,574 5,483,832
Loss from operations (3,080,094) (5,484,631)
Other income:    
Change in fair value of warrant liabilities 421,700 1,206,997
Interest expense  
Interest income  
Foreign currency exchange gain/(loss)
Gain on forgiveness of accounts payable 45,000
Other income 421,700 1,251,997
Loss before income taxes (2,658,394) (4,232,634)
Provision for income taxes
Net loss (2,658,394) (4,232,634)
ALPHA 5 INTEGRIN, LLC [Member]    
Acquired Indefinite-Lived Intangible Assets [Line Items]    
Revenues
Cost of services  
Gross margin
Operating expenses:    
Selling, general and administrative 432,832 978,223
Loss from operations (432,832) (978,223)
Other income:    
Change in fair value of warrant liabilities
Interest expense  
Interest income  
Foreign currency exchange gain/(loss) (173) (4,884)
Gain on forgiveness of accounts payable
Other income (173) (4,884)
Loss before income taxes (432,659) (983,107)
Provision for income taxes
Net loss (432,659) (983,107)
PRO FROMA PASITHEA THERAPEUTICS CORP [Member]    
Acquired Indefinite-Lived Intangible Assets [Line Items]    
Revenues 13,581 27,239
Cost of services 15,101 28,038
Gross margin (1,520) (799)
Operating expenses:    
Selling, general and administrative 3,511,406 6,462,055
Loss from operations (3,512,926) (6,462,854)
Other income:    
Change in fair value of warrant liabilities 421,700 1,206,997
Interest expense  
Interest income  
Foreign currency exchange gain/(loss) (173) (4,884)
Gain on forgiveness of accounts payable 45,000
Other income 421,527 1,247,113
Loss before income taxes (3,091,053) (5,215,741)
Net loss $ (3,091,053) $ (5,215,741)
Weighted-average common shares outstanding, basic and diluted (in Shares) 23,373,347 23,190,859
Basic and diluted net loss per common share (in Dollars per share) $ (0.13) $ (0.22)